WO1997034920B1 - Dosages pour inhibiteurs du recepteur tyrosine kinase kdr/flk-1 - Google Patents
Dosages pour inhibiteurs du recepteur tyrosine kinase kdr/flk-1Info
- Publication number
- WO1997034920B1 WO1997034920B1 PCT/US1997/003378 US9703378W WO9734920B1 WO 1997034920 B1 WO1997034920 B1 WO 1997034920B1 US 9703378 W US9703378 W US 9703378W WO 9734920 B1 WO9734920 B1 WO 9734920B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vegf
- subset
- receptor
- candidate compounds
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
La présente invention concerne des procédés d'identification de composés et des compositions pharmaceutiques capables d'inhiber sélectivement et potentiellement la transduction du signal de tyrosine kinase KDR/FLK-1 afin d'inhiber la vasculogénèse et/ou l'angiogénèse. La présente invention concerne également des composés et des compositions identifiés à l'aide des procédés de l'invention ainsi que leur utilisation dans le traitement de maladies relatives à une vasculogénèse et/ou une angiogénèse inappropriées.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU20667/97A AU2066797A (en) | 1996-03-21 | 1997-03-04 | Assays for kdr/flk-1 receptor tyrosine kinase inhibitors |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62173496A | 1996-03-21 | 1996-03-21 | |
| US08/621,734 | 1996-03-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997034920A1 WO1997034920A1 (fr) | 1997-09-25 |
| WO1997034920B1 true WO1997034920B1 (fr) | 1997-10-30 |
Family
ID=24491410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/003378 Ceased WO1997034920A1 (fr) | 1996-03-21 | 1997-03-04 | Dosages pour inhibiteurs du recepteur tyrosine kinase kdr/flk-1 |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2066797A (fr) |
| WO (1) | WO1997034920A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| WO1998024432A2 (fr) * | 1996-12-05 | 1998-06-11 | Sugen, Inc. | Utilisation de composes a base d'indolinone en tant que modulateurs de proteine kinases |
| AU3850299A (en) * | 1998-05-20 | 1999-12-06 | Kyowa Hakko Kogyo Co. Ltd. | Vegf activity inhibitors |
| JP2002517241A (ja) | 1998-06-11 | 2002-06-18 | アストラゼネカ アクチボラグ | ヒト受容体チロシンキナーゼ |
| ES2291041T3 (es) * | 1998-08-13 | 2008-02-16 | Novartis Ag | Metodo para tratar enfermedades neovasculares oculares. |
| IL142757A0 (en) * | 1998-11-23 | 2002-03-10 | Novartis Ag | Use of staurosporine derivatives for treating ocular neovascular diseases |
| US6214819B1 (en) | 1998-11-23 | 2001-04-10 | Novartis Ag | Method for treating ocular neovascular diseases |
| GB9918057D0 (en) * | 1999-07-30 | 1999-10-06 | Univ Bristol | Therapeutic agents |
| US6271233B1 (en) | 1999-08-10 | 2001-08-07 | Ciba Vision Corporation | Method for treating ocular neovascular diseases |
| MXPA02001439A (es) * | 1999-08-11 | 2002-08-30 | Eos Biotechnology Inc | Nuevos metodos para el diagnostico de angiogenesis, composiciones y metodos de exhibicion de moduladores de la angiogenesis. |
| WO2001031346A2 (fr) * | 1999-10-28 | 2001-05-03 | The Procter & Gamble Company | Utilisation d'un complexe de vegfr-2 et de neuropilin-1 dans l'identification de nouvelles substances actives pro-angiogeniques et anti-angiogeniques |
| BRPI0108394B8 (pt) | 2000-02-15 | 2021-05-25 | Upjohn Co | inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos |
| CA2411072A1 (fr) * | 2000-06-07 | 2001-12-13 | Ortho-Mcneil Pharmaceutical, Inc. | Methode permettant de detecter des modulateurs du domaine kinase du recepteur du vegf |
| EP1311277A4 (fr) * | 2000-07-18 | 2004-08-25 | Joslin Diabetes Center Inc | Procede de modulation de fibrose |
| AR042586A1 (es) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| US6649367B2 (en) * | 2001-03-22 | 2003-11-18 | Eisai Co., Ltd | Human cancer cell line malignantly altered by expression of angiogenic factor |
| US7268137B2 (en) * | 2002-11-07 | 2007-09-11 | Campochiaro Peter A | Ocular therapy |
| AU2011211380B9 (en) * | 2004-04-30 | 2014-05-08 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitor implants |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| BRPI0510485A (pt) | 2004-04-30 | 2007-11-13 | Allergan Inc | implantes inibidores de tirosina cinase intravìtreos biodegradáveis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5700823A (en) * | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| US5840301A (en) * | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
-
1997
- 1997-03-04 WO PCT/US1997/003378 patent/WO1997034920A1/fr not_active Ceased
- 1997-03-04 AU AU20667/97A patent/AU2066797A/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997034920B1 (fr) | Dosages pour inhibiteurs du recepteur tyrosine kinase kdr/flk-1 | |
| DE69938623T2 (de) | Microarrays und ihre verwendungen | |
| Kaipainen et al. | Enhanced expression of the tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas | |
| Chang et al. | Morphine activation of c-fos expression in rat brain | |
| Kirkin et al. | Characterization of indolinones which preferentially inhibit VEGF‐C‐and VEGF‐D‐induced activation of VEGFR‐3 rather than VEGFR‐2 | |
| Wang et al. | Eph family transmembrane ligands can mediate repulsive guidance of trunk neural crest migration and motor axon outgrowth | |
| Nakagawa et al. | Combinatorial expression patterns of LIM-homeodomain and other regulatory genes parcellate developing thalamus | |
| Dong et al. | Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor | |
| Wang et al. | Negative regulators of cell growth | |
| DE60026592T2 (de) | Betaglycan als ein inhibin rezeptor und dessen verwendung | |
| Pennypacker et al. | Kainate‐induced changes in opioid peptide genes and AP‐1 protein expression in the rat hippocampus | |
| CA2375820C (fr) | Promoteur du gene de la myostatine et methode pouvant inhiber l'activation dudit promoteur | |
| Fujiki et al. | Tumor necrosis factor-α, a new tumor promoter, engendered by biochemical studies of okadaic acid | |
| Rage et al. | Targeting transforming growth factor α expression to discrete loci of the neuroendocrine brain induces female sexual precocity | |
| CN101283275A (zh) | 趋化因子表达的依赖egfr的调控和对肿瘤的诊断和治疗的影响及其副作用 | |
| Wu et al. | The proximal serum response element in the Egr-1 promoter mediates response to thrombin in primary human endothelial cells | |
| Yeo et al. | Transcription factor EGR-1 transactivates the MMP1 gene promoter in response to TNFα in HaCaT keratinocytes | |
| DE19957065B4 (de) | Screening-Verfahren für Arzneistoffe | |
| Blanchard et al. | Chromatin reader L (3) mbt requires the Myb–MuvB/DREAM transcriptional regulatory complex for chromosomal recruitment | |
| Deng et al. | BDNF is involved in sympathetic sprouting in the dorsal root ganglia following peripheral nerve injury in rats | |
| KR102020899B1 (ko) | 수용성 공통 감마 수용체 저해제인 압타머를 포함하는 자가면역질환 예방 또는 치료용 약학적 조성물 | |
| Bianchi et al. | EphB receptors influence growth of ephrin‐B1‐positive statoacoustic nerve fibers | |
| Liang et al. | Id4 and FABP7 are preferentially expressed in cells with astrocytic features in oligodendrogliomas and oligoastrocytomas | |
| EP1282827B1 (fr) | Procede de selection d'inhibiteurs d'enzymes | |
| EP0960937A4 (fr) | Nouveau gene de semaphorine: semaphorine y |